Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04192370 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04192370: Completed Phase 2 study, sponsored by Brigham and Women's Hospital.
NCT04192370 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04192370, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this week-long study is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine treatment.
Primary Outcome
Change in cue-induced cravings and anxiety measured before and after 3 days of cannabidiol administration. Subjects will use the Cue-Induced Opioid Craving and Anxiety Scales to note their responses using a visual analog scale of 0 to 10, 0 being "not at all" and 10 being "extremely." Higher scores thus mean a "worse" outcome (i.e. more intense cravings/anxiety).
Interventions
- DRUG Cannabidiol 600mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-08-03 |
| Est. Completion | 2021-12-30 |
| Phase | Phase 2 |
What the finished NCT04192370 record still lists
NCT04192370 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Cannabidiol 600mg is the first listed.
NCT04192370 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04192370 about?
NCT04192370 is a clinical study titled "Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine". The purpose of this week-long study is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine treatment.
What is the current status of trial NCT04192370?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-08-03. Estimated completion is 2021-12-30.
What interventions are being tested in trial NCT04192370?
The interventions under investigation include: Cannabidiol 600mg (DRUG).
Who is sponsoring clinical trial NCT04192370?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04192370's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI